ZURA - NASDAQ
Zura Bio Limited
$4.10
-5.9%Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
At a Glance
Live Snapshotzura
Total Liabilities
Last Annual Value
12.41M
3-Year CAGR
-23%
5-Year CAGR
4%
10-Year CAGR
2%
Zura Bio Limited Competitors Analysis of Total Liabilities
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
 Zura Bio Limited NASDAQ:ZURA | 12.41M | -16.5% | 3.7% | N/A | |
 Pyxis Oncology, Inc. NASDAQ:PYXS | 38.11M | -7.4% | 15.3% | N/A | |
 Caribou Biosciences, Inc. NASDAQ:CRBU | 53.19M | -5.9% | -0.5% | N/A | |
 Neonc Technologies Holdings, Inc. NASDAQ:NTHI | 20.33M | 10.1% | 50.3% | N/A | |
 SELLAS Life Sciences Group, Inc. NASDAQ:SLS | 7.47M | -19.3% | 4.2% | -14.8% | |
 Entrada Therapeutics, Inc. NASDAQ:TRDA | 71.25M | -32.0% | 58.5% | N/A | |
 Aardvark Therapeutics, Inc. Common Stock NASDAQ:AARD | 10.55M | -38.5% | N/A | N/A | |
 Immuneering Corporation NASDAQ:IMRX | 13.50M | 4.0% | 4.7% | N/A | |
 Tenaya Therapeutics, Inc. NASDAQ:TNYA | 23.66M | -8.7% | -9.1% | N/A | |
 Sagimet Biosciences Inc. NASDAQ:SGMT | 5.10M | -3.4% | -52.8% | N/A | |
 Assembly Biosciences, Inc. NASDAQ:ASMB | 50.84M | -19.0% | 18.1% | 10.8% |
Zura Bio Limited Fair Value Envelope
Related Guides
Continue your ZURA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.